ArticleVaccines2025
Demographic and Clinical Characteristics of Patients Vaccinated Against Herpes Zoster in a Primary Care Setting in Spain: A Retrospective Study.
Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Herpes zoster hospitalization burden in Spain during the initial period of recombinant zoster vaccine implementation.Human vaccines & immunotherapeutics · 2026Article
- From Knowledge to Action: Enhancing Herpes Zoster Vaccine Uptake in Diabetic Patients Through Targeted Interventions.Vaccines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHerpes zoster (HZ), commonly known as shingles, is a reactivation of the varicella-zoster virus that predominantly affects older adults and immunocompromised individuals. Vaccination with the recombinant zoster vaccine (RZV) has proven effective in preventing HZ and its complications in real-world scenarios, yet coverage remains suboptimal in primary care settings. This study aims to analyse the demographic and clinical characteristics of HZ-vaccinated patients in a primary care centre in Madrid, Spain, in 2023 and to assess adherence to the vaccination schedule.
methodsA retrospective descriptive analysis was conducted, including 1146 patients from a single primary care centre who received at least one dose of RZV during the study period. Data were extracted from medical records. Patient characteristics, including age, sex, and the presence of comorbidities (e.g., diabetes, chronic obstructive pulmonary disease, hypertension, asthma), were examined. Vaccine coverage was calculated for the new age cohorts introduced in the year 2023. Comorbidity prevalence was also analysed by age and sex to determine patterns in vaccination uptake.
resultsThe analysis revealed that 66% of vaccinated individuals presented one or more of the analysed comorbidities. Adherence to the two-dose schedule was 91.97%, and vaccine coverages were 46.56% in those born between 1943-1948 and 39.32% in the 1958 cohort. The findings underscore the need for targeted strategies to raise disease awareness and improve HZ vaccination rates and adherence, particularly among elderly individuals and those with comorbid conditions.
conclusionsThis study specifies the clinical characteristics of HZ-vaccinated patients in a primary care setting and highlights the importance of enhanced vaccination awareness and adherence strategies to reduce the burden of HZ among at-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.